|
|||||
|
|
Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations |
|
| Authors: | Francesca Khani Sara E Wobker Jessica L Hicks Brian D Robinson Christopher E Barbieri Angelo M De Marzo Jonathan I Epstein Colin C Pritchard Tamara L Lotan |
| Affiliation: | 1. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA;2. Department of Pathology and Laboratory Medicine, UNC Chapel Hill, Chapel Hill, NC, USA;3. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA;4. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA Department of Urology, Weill Cornell Medicine, New York, NY, USA;5. Department of Urology, Weill Cornell Medicine, New York, NY, USA;6. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA;7. Department of Laboratory Medicine, University of Washington, Seattle, WA, USA;8. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA |
| Abstract: | Intraductal carcinoma of the prostate (IDC-P) most often appears associated with high-grade invasive prostate carcinoma (PCa), where it is believed to represent retrograde spread. However, IDC-P rarely occurs as an isolated finding at radical prostatectomy or with concurrent low-grade (Grade Group 1) invasive carcinoma. We hypothesized that isolated IDC-P (iIDC-P) in these unusual cases may represent a distinct in situ lesion and molecularly profiled 15 cases. iIDC-P was characterized by copy number alteration (CNA) profiling and targeted next generation sequencing in cases with sufficient tissue (n = 7). Immunohistochemistry for PTEN and ERG was performed on the total cohort (n = 15), where areas of iIDC-P and associated invasive disease were evaluated separately (n = 9). By copy number profiling, iIDC-P alterations were similar to those previously described in high-grade invasive PCa (PTEN, RB1, and CHD1 loss; MYC gain). However, in four cases, targeted sequencing revealed a striking number of activating oncogenic driver mutations in MAPK and PI3K pathway genes, which are extraordinarily rare in conventional PCa. In addition, pathogenic mutations in DNA repair genes were found in two cases of iIDC-P (BRCA2, CHEK2, CDK12) and other known PCa-associated mutations (FOXA1, SPOP) in two cases. Overall, ERG was expressed in 7% (1/15) of the iIDC-P lesions and PTEN was lost in 53% (8/15). Discordance for ERG or PTEN status between IDC-P and the low-grade PCa was observed in five of nine cases, with intact PTEN in the invasive tumor and PTEN loss in IDC-P in four. Despite a CNA profile similar to conventional PCa, iIDC-P is enriched with potentially targetable oncogenic driver mutations in MAPK/PI3K genes. Based on PTEN and ERG status, iIDC-P is not likely a precursor to the associated low-grade invasive PCa, but represents a molecularly unique in situ tumor of unclear clinical significance. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
| Keywords: | intraductal carcinoma prostate cancer oncogenic driver mutations MAPK PI3K |